Goldman Sachs’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Goldman Sachs’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-200,000	Closed	-$20.6M	–	6087
2023 Q2	$20.6M	Buy	200,000 +194,600	+3,604%	+$20.5M	﹤0.01%	1822
2023 Q1	$589K	Hold	5,400	–	–	﹤0.01%	4740
2022 Q4	$615K	Buy	+5,400	New	+$449K	﹤0.01%	4747
2022 Q1	–	Sell	-5,000	Closed	-$539K	–	7195
2021 Q4	$539K	Hold	5,000	–	–	﹤0.01%	5321
2021 Q3	$548K	Hold	5,000	–	–	﹤0.01%	5139
2021 Q2	$468K	Hold	5,000	–	–	﹤0.01%	5263
2021 Q1	$460K	Sell	5,000 -16,900	-77%	-$1.43M	﹤0.01%	5190
2020 Q4	$1.6M	Hold	21,900	–	–	﹤0.01%	3887
2020 Q3	$1.7M	Buy	+21,900	New	+$1.51M	﹤0.01%	3686
2018 Q1	–	Sell	-50,000	Closed	-$730K	–	6606
2017 Q4	$730K	Sell	50,000 -6,400	-11%	-$89.9K	﹤0.01%	4541
2017 Q3	$715K	Sell	56,400 -913,600	-94%	-$11.6M	﹤0.01%	4846
2017 Q2	$11.5M	Hold	970,000	–	–	﹤0.01%	2395
2017 Q1	$14.3M	Buy	970,000 +615,800	+174%	+$9.97M	﹤0.01%	2139
2016 Q4	$5.73M	Buy	354,200 +254,200	+254%	+$4.61M	﹤0.01%	2937
2016 Q3	$1.81M	Buy	100,000 +73,300	+275%	+$1.43M	﹤0.01%	3920
2016 Q2	$440K	Sell	26,700 -248,300	-90%	-$4.02M	﹤0.01%	4965
2016 Q1	$4.56M	Sell	275,000 -246,600	-47%	-$4.31M	﹤0.01%	2792
2015 Q4	$11.3M	Sell	521,600 -937,900	-64%	-$18.3M	﹤0.01%	2161
2015 Q3	$28.9M	Buy	1,459,500 +959,500	+192%	+$30.3M	0.01%	1447
2015 Q2	$17.4M	Buy	+500,000	New	+$15.3M	0.01%	1905
2014 Q2	–	Sell	-289,000	Closed	-$4.37M	–	7233
2014 Q1	$4.37M	Buy	+289,000	New	+$3.26M	﹤0.01%	3176

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's HZNP Position: Q4 2023 in Review

Goldman Sachs sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 698,361 shares — an estimated $80.8M sold.

Goldman Sachs first reported a position in HZNP in Q2 2013 and held it in 42 quarters. The position peaked at $161M in Q1 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Goldman Sachs reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Goldman Sachs sold 698,361 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $80.8M.
Goldman Sachs first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 42 quarters.
Goldman Sachs's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $161M in Q1 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Goldman Sachs's 13F filing for Q4 2023, filed 13 Feb 2024.